Annovis Bio, Inc.
ANVSNYSE
$1.74
0.0%Jul 17 close · end-of-day
Price
1Y↓ -36.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$48.5M
Enterprise Value
$34.2M
P/E
—
P/S
—
P/B
15.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$40.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-1309.1%
ROIC
—
Debt / Equity
—
Net Cash
$14.2M
Return 1Y
-38.1%
Company profile
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for Alzheimer's disease.
- CEO
- Maria-Luisa Maccecchini
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3
- Headquarters
- Pennsylvania
- Website
- annovisbio.com
Management & directors
- Maccecchini Maria-LuisaPresident & CEO
- Walsh AndrewVice President, Finance
Roles derived from SEC Form 4 filings.
Earnings
ANVS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.63↑ +96.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.6M | -$14.5M | -$25.5M | -$45.0M | -$26.7M | -$29.7M |
| Net income | -$5.5M | -$14.5M | -$25.3M | -$56.2M | -$24.6M | -$28.9M |
| Diluted EPS | -$0.87 | -$1.90 | -$3.10 | -$6.23 | -$2.31 | -$1.40 |
| Operating cash flow | -$4.0M | -$9.1M | -$17.3M | -$40.0M | -$21.9M | -$25.6M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.8M | -$4.4M | -$6.7M | -$6.3M | -$6.3M | -$7.4M | -$9.7M | -$18.0M |
| Net income | -$5.0M | -$12.6M | -$5.9M | -$5.5M | -$6.2M | -$7.3M | -$9.8M | -$17.6M |
| Diluted EPS | -$0.44 | -$0.97 | -$0.18 | -$0.32 | -$0.32 | -$0.37 | -$0.39 | -$0.63 |
| Operating cash flow | -$3.4M | -$3.2M | -$8.3M | -$8.1M | -$5.1M | -$3.5M | -$8.9M | -$9.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 7, 2026
May 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-20 | Hoffman Michael B | Buy | 54,933 | $1.90 | $104,367.21 | filing |
| 2026-05-20 | Hoffman Michael B | Buy | 18,849 | $1.80 | $33,928.20 | filing |
| 2026-05-20 | Hoffman Michael B | Buy | 2,562 | $1.75 | $4,483.50 | filing |
| 2026-04-02 | Hoffman Michael B | Buy | 713,800 | $2.10 | $1.5M | filing |
| 2025-12-08 | Hoffman Michael B | Buy | 30,000 | $4.34 | $130,194.00 | filing |
| 2025-12-08 | Hoffman Michael B | Buy | 15,000 | $4.24 | $63,600.00 | filing |
| 2025-11-24 | Hoffman Michael B | Buy | 28,096 | $4.15 | $116,598.40 | filing |
| 2025-11-24 | Hoffman Michael B | Buy | 28,096 | $4.15 | $116,598.40 | filing |
| 2025-11-24 | Hoffman Michael B | Buy | 9,200 | $3.85 | $35,420.00 | filing |
| 2025-11-24 | Hoffman Michael B | Buy | 9,200 | $3.85 | $35,420.00 | filing |
| 2025-11-24 | Hoffman Michael B | Buy | 1,489 | $4.13 | $6,149.57 | filing |
| 2025-11-24 | Hoffman Michael B | Buy | 1,489 | $4.13 | $6,149.57 | filing |
| 2025-11-24 | Hoffman Michael B | Buy | 415 | $4.14 | $1,718.10 | filing |
| 2025-11-24 | Hoffman Michael B | Buy | 415 | $4.14 | $1,718.10 | filing |
| 2025-11-21 | Hoffman Michael B | Buy | 10,000 | $3.50 | $35,000.00 | filing |
| 2025-11-21 | Hoffman Michael B | Buy | 10,000 | $3.49 | $34,900.00 | filing |
| 2025-11-14 | Hoffman Michael B | Buy | 15,000 | $2.11 | $31,650.00 | filing |
| 2025-10-28 | Hoffman Michael B | Buy | 975,610 | $2.05 | $2.0M | filing |
| 2025-10-28 | Maccecchini Maria-Luisa· President & CEO | Buy | 97,561 | $2.05 | $200,000.05 | filing |
| 2025-09-10 | Bruck Claudine | Option exercise | 7,142 | $0.14 | $999.88 | filing |
| 2025-08-29 | Hoffman Michael B | Award | 5,000 | $2.30 | $11,500.00 | filing |
| 2025-08-29 | Hoffman Michael B | Award | 5,000 | $2.29 | $11,450.00 | filing |
| 2025-08-29 | Hoffman Michael B | Award | 5,000 | $2.28 | $11,400.00 | filing |
| 2025-08-19 | Hoffman Michael B | Award | 6,717 | $2.60 | $17,464.20 | filing |
| 2025-08-19 | Hoffman Michael B | Award | 5,545 | $2.58 | $14,306.10 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.